PPT-ASAM LEVEL 3.1 RESIDENTIAL TREATMENT PROVIDERS STAKEHOLDERS MEETING
Author : tawny-fly | Published Date : 2019-11-23
ASAM LEVEL 31 RESIDENTIAL TREATMENT PROVIDERS STAKEHOLDERS MEETING MedicaidBehavioral Health Administration BHABeacon Health Options MARYLAND DEPARTMENT OF HEALTH
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "ASAM LEVEL 3.1 RESIDENTIAL TREATMENT PRO..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
ASAM LEVEL 3.1 RESIDENTIAL TREATMENT PROVIDERS STAKEHOLDERS MEETING: Transcript
ASAM LEVEL 31 RESIDENTIAL TREATMENT PROVIDERS STAKEHOLDERS MEETING MedicaidBehavioral Health Administration BHABeacon Health Options MARYLAND DEPARTMENT OF HEALTH Marian Bland LCSWC Director Clinical Services BHA. brPage 1br RESIDENTIAL DRUG TREATMENT PROGRAM LOCATIONS NORTHEAST REGION FCI Allenwood Low PA FCI Allenwood Med PA FCI Berlin NH USP Canaan PA FCI Danbury CT FCI Elkton OH FCI Fairto The Power of Authentic Engagement. Download the Blueprint: . . www.ideapartnership.org. Coalescing around Issues. Adaptive/Human Elements. Technical Elements. . Value each and all perspectives . Acknowledge individuality of language. Douglas N. Brush, CACII. Director, Men’s Recovery Center. MARR, Inc.. MARR Components of Care. Abstinence based. Minimum 90-day intensive residential structure. Gender separate, gender specific. Intensive clinical services. Upstream. (Manufacturer/model – Wholesale). Midstream. (Customers – Retail). Downstream. (Direct Install, Streetlights, Municipal Retrofits). New Construction . (Residential and Commercial). Residential upstream incentives (e.g. at the manufacture or distributor level). Upstream. (Manufacturer/model – Wholesale). Midstream. (Customers – Retail). Downstream. (Direct Install, Streetlights, Municipal Retrofits). New Construction . (Residential and Commercial). Residential upstream incentives (e.g. at the manufacture or distributor level). Ohio Department of Medicaid. March 9, 2017. Medicaid Behavioral Health Redesign. in Ohio Hospitals. 3/7/2017 . 2. . Behavioral Health Redesign was developed for community behavioral health agencies who employ a variety of practitioners. & . Short-Term Residential . Substance Use Disorder Treatment. Services RFPs. Bidder’s Conference. August . 9, 2016. 2. Department of Children and Families (DCF). Created in July 2006. First Cabinet-level Department devoted . Don’t get information overload. Ray . Caesar LPC, LADC-MH. Director of Addiction Specialty Programs. ODMHSAS. (405)522-3870. rcaesar@odmhsas.org. Nisha Wilson, LPC. Director of . Specialty Courts. ODMHSAS. to choose the facility and level of Care. . CAPTASA 2015. Lexington, KY. The Practice Gap. Many people are not placed in optimal treatment environments. Often, decisions driven more by administrative or patient preference, rather than clinical needs. Substance Use Disorder (SUD) Residential Treatment Agenda MHS SUD Residential Treatment Enrollment Claim Submission 2 Residential SUD Treatment Provider Enrollment Effective March 1, 2018, IHCP established a Involuntary Hospitalization Task Force. July 26, 2019. Post Stabilization and Community Support Work Group. Objective: To catalog the continuum of mental health and substance use resources available throughout the state. Includes the following:. Policy Compliance and Workforce Development. Purpose. DSAMH Provider Enrollment Technical Assistance . A telephone or email communication from community provider with inquiry on how to become a behavioral health and /or substance use disorder treatment provider.. Identifying symptoms and treatment strategies for substance abusing parents.. Crystal Bartlett, LPC, CADC II. DSM 5 Substance Use Disorder Criteria. Criterion. Severity. More use than intended. 0-1: No diagnosis. Louis E. Baxter, Sr., MD, DFASAM. The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine Webinar. July 19, 2017. Louis E. Baxter, Sr., MD, DFASAM. No disclosures. Why Do We Need This .
Download Document
Here is the link to download the presentation.
"ASAM LEVEL 3.1 RESIDENTIAL TREATMENT PROVIDERS STAKEHOLDERS MEETING"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents